FREMONT, Calif., Jan. 13, 2026 /PRNewswire/ — Alamar Biosciences, Inc. (“Alamar”), a pacesetter in precision proteomics devoted to advancing the early detection of illness, is proud to announce the launch of its Analysis Use Solely (RUO) NULISAqpcr™ AD 5-plex Assay. This modern answer permits simultaneous quantitative measurement of 5 vital blood-based biomarkers related to the Alzheimer’s Affiliation really useful pointers: brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament mild chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and APOE4 (provider standing), all from a single blood or plasma pattern.
NULISAqpcr AD 5-plex Assay contains BD-pTau217, GFAP, NfL, AB42 and APOE4.
The NULISAqpcr AD 5-plex Assay consolidates key biomarkers right into a single multiplexed format, delivering unmatched sensitivity, specificity, and ease of use. By incorporating BD-pTau217, Aβ42, NfL, and GFAP, the assay permits sturdy monitoring of amyloid and tau pathology, neurodegeneration, and irritation, whereas precisely figuring out APOE4 provider standing—the strongest genetic threat issue for Alzheimer’s illness. Collectively, these capabilities create a robust device for each translational and scientific analysis, and its relevance extends past Alzheimer’s illness to different neurodegenerative and cognitive problems.
“The launch of the NULISAqpcr AD 5-plex Assay marks a major milestone in our efforts to ship precision proteomics options for neurodegenerative illness,” stated Dr. Yuling Luo, founder, chairman and chief government officer of Alamar. “By combining these vital protein targets right into a single assay with a streamlined workflow, we’re empowering the neuroscience group to advance screening, early detection and precision diagnoses for Alzheimer’s illness.”
“Blood-based biomarkers are redefining Alzheimer’s analysis, offering an correct, cheaper and extra accessible means of creating early analysis and aiding dedication of eligibility for therapies,” stated Dr. Steven Williams, chief scientific officer of Alamar. “Conventional single-plex assays can measure these biomarkers individually, however require a number of exams to supply a complete view of the illness. With NULISA™ it’s now potential to measure a number of Alzheimer’s-related proteins in blood, every providing distinctive insights into the underlying pathophysiology.”
Alamar is devoted to collaborating with researchers, clinicians, and business companions to unlock precision proteomics and enhance outcomes for sufferers affected by Alzheimer’s illness and different neurodegenerative circumstances. The NULISAqpcr AD 5-plex Assay is obtainable right now as a service by our Expertise Entry Program.
For extra details about the NULISAqpcr AD 5-plex Assay and Alamar’s full portfolio of precision proteomic options, go to www.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences firm devoted to powering precision proteomics to allow the earliest detection of illness. Leveraging its proprietary NULISA™ know-how and the ARGO™ HT System, Alamar’s platform is designed to ship ultra-high sensitivity and addresses key limitations of present applied sciences to ship precision proteomics. For extra info, please go to alamarbio.com.
